Disease-specific overall survival in endometrioid ovarian

CD44 Is a Prognostic Biomarker Correlated With Immune Infiltrates and Metastasis in Clear Cell Renal Cell Carcinoma

Targeted Therapy in Ovarian Cancer Published in healthbook TIMES Oncology Hematology

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease- Specific Death - Modern Pathology

Novel Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Uncovered by Data-Independent Acquisition Mass Spectrometry

The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas

Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study, Journal of Ovarian Research

Endometrial, Ovarian, and Cervical Cancer

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers, BMC Cancer

Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone

How is ovarian cancer treated?

Diagnostics, Free Full-Text